Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice

Neuroscience

Volumn 263, Issue , 2014, Pages 1-14

  Guo, J ^a   Lin, P ^a   Zhao, X ^a   Zhang, J ^a   Wei, X ^a   Wang, Q ^a   Wang, C ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Cyclic adenosine monophosphate (cAMP); Depression; Etazolate; Interleukin 1 (IL 1 ); Lipopolysaccharide (LPS); Phosphodiesterase 4 (PDE4)

Indexed keywords

CYCLIC ADENOSINE MONOPHOSPHATE (CAMP); DEPRESSION; ETAZOLATE; INTERLEUKIN-1Β (IL-1Β); LIPOPOLYSACCHARIDE (LPS); PHOSPHODIESTERASE-4 (PDE4);

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DEPRESSION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ETAZOLATE; HIPPOCAMPUS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; PHOSPHODIESTERASE INHIBITORS; PREFRONTAL CORTEX;

EID: 84893686575     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.01.008     Document Type: Article

References (74)

1. Anderson G.M., Barr C.S., Lindell S., Durham A.C., Shifrovich I., Higley J.D. Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the rhesus monkey. Psychopharmacology (Berl) 2005, 178:339-346.
2. Bekris S., Antoniou K., Daskas S., Papadopoulou-Daifoti Z. Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. Behav Brain Res 2005, 161:45-59.
3. Breuillaud L., Rossetti C., Meylan E.M., Mérinat C., Halfon O., Magistretti P.J., Cardinaux J.R. Deletion of CREB-regulated transcription coactivator 1 induces pathological aggression, depression-related behaviors, and neuroplasticity genes dysregulation in mice. Biol Psychiatry 2012, 72:528-536.
4. Cheng Y.F., Wang C., Lin H.B., Li Y.F., Huang Y., Xu J.P., Zhang H.T. Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Psychopharmacology (Berl) 2010, 212:181-191.
5. Ching S., Zhang H., Belevych N., He L., Lai W., Pu X.A., Jaeger L.B., Chen Q., Quan N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J Neurosci 2007, 27:10476-10486.
6. Dagyte G., Luiten P.G., De Jager T., Gabriel C., Mocaër E., Den Boer J.A., Van der Zee E.A. Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain. J Neurosci Res 2011, 89:1646-1657.
7. Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin 2006, 24:441-460.
8. Dantzer R. Depression and inflammation: an intricate relationship. Biol Psychiatry 2012, 71:4-5.
9. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
10. Drott J., Desire L., Drouin D., Pando M., Haun F. Etazolate improves performance in a foraging and homing task in aged rats. Eur J Pharmacol 2010, 634:95-100.
11. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
12. Dworkin S., Malaterre J., Hollande F., Darcy P.K., Ramsay R.G., Mantamadiotis T. CAMP response element binding protein is required for mouse neural progenitor cell survival and expansion. Stem Cells 2009, 27:1347-1357.
13. Dyke H.J., Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002, 11:1-13.
14. Fan L.W., Kaizaki A., Tien L.T., Pang Y., Tanaka S., Numazawa S., Bhatt A.J., Cai Z. Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats. Neuroscience 2013, 240:27-38.
15. Fujimaki K., Morinobu S., Duman R.S. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 2000, 22:42-51.
16. Fuller-Thomson E., Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006, 12:697-707.
17. Gałecki P., Gałecka E., Maes M., Chamielec M., Orzechowska A., Bobińska K., Lewiński A., Szemraj J. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 2012, 138:360-366.
18. Gárate I., Garcia-Bueno B., Madrigal J.L., Caso J.R., Alou L., Gomez-Lus M.L., Micó J.A., Leza J.C. Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry 2013, 73:32-43.
19. Gobejishvili L., Barve S., Breitkopf-Heinlein K., Li Y., Zhang J., Avila D.V., Dooley S., McClain C.J. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4. J Pharmacol Exp Ther 2013, 347:80-90.
20. Goltser-Dubner T., Galili-Weisstub E., Segman R.H. Genetics of unipolar major depressive disorder. Isr J Psychiatry Relat Sci 2010, 47:72-82.
21. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry 2010, 9:155-1561.
22. Hedayati S.S., Minhajuddin A.T., Afshar M., Toto R.D., Trivedi M.H., Rush A.J. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA 2010, 303:1946-1953.
23. Hedlund P.B., Huitron-Resendiz S., Henriksen S.J., Sutcliffe J.G. 5-HT7 receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern. Biol Psychiatry 2005, 58:831-837.
24. Ji W.W., Wang S.Y., Ma Z.Q., Li R.P., Li S.S., Xue J.S., Li W., Niu X.X., Yan L., Zhang X., Fu Q., Qu R., Ma S.P. Effects of perillaldehyde on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 2013, doi:pii: S0091-3057(13)00272-4.
25. Jindal A., Mahesh R., Gautam B., Bhatt S., Pandey D. Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor-an approach using rodent behavioral antidepressant tests battery. Eur J Pharmacol 2012, 689:125-131.
26. Kentner A.C., McLeod S.A., Field E.F., Pittman Q.J. Sex-dependent effects of neonatal inflammation on adult inflammatory markers and behavior. Endocrinology 2010, 151:2689-2699.
27. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 1995, 274:866-876.
28. Krogh J., Benros M.E., Jørgensen M.B., Vesterager L., Elfving B., Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun 2013, pii: S0889-1591(13)00448-0.
29. Lawson M.A., Parrott J.M., McCusker R.H., Dantzer R., Kelley K.W.O., Connor J.C. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J Neuroinflammation 2013, 10:87.
30. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
31. Li Y.F., Huang Y., Amsdell S.L., Xiao L., O'Donnell J.M., Zhang H.T. Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 2009, 34:2404-2419.
32. Li Y.F., Cheng Y.F., Huang Y., Conti M., Wilson S.P., O'Donnell J.M., Zhang H.T. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 2011, 31:172-1783.
33. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008, 29:287-291.
34. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 35:664-675.
35. Maes M., Berk M., Goehler L., Song C., Anderson G., Gałecki P., Leonard B. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012, 10:66.
36. Maillet M., Robert S.J., Cacquevel M., Gastineau M., Vivien D., Bertoglio J., Zugaza J.L., Fischmeister R., Lezoualc'h F. Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat Cell Biol 2003, 5:633-639.
37. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001, 35:5-49.
38. Marsden W.N. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry 2013, 43:168-184.
39. Miró X., Pérez-Torres S., Puigdomènech P., Palacios J.M., Mengod G. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 2002, 45:259-269.
40. Moore A.R., Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 1995, 101(3):387-389.
41. Moreau M., Lestage J., Verrier D., Mormede C., Kelley K.W., Dantzer R., Castanon N. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis 2005, 192:537-544.
42. Moss S.J., Smart T.G., Blackstone C.D., Huganir R.L. Functional modulation of GABAA receptors by cAMP-dependent protein phosphorylation. Science 1992, 257:661-665.
43. Nemeroff C.B. Stress, menopause and vulnerability for psychiatric illness. Expert Rev Neurother 2007, 7:S11-S13.
44. Niciu M.J., Ionescu D.F., Mathews D.C., Richards E.M., Zarate C.A. Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr 2013, 1-10.
45. O'Connor J.C., Lawson M.A., André C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
46. O'Donnell J.M., Frith S. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 1999, 63:185-192.
47. Park S.E., Dantzer R., Kelley K.W., McCusker R.H. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J Neuroinflammation 2011, 8:12.
48. Patki G., Solanki N., Atrooz F., Allam F., Salim S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res 2013, pii: S0006-8993(13)01307-3.
49. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
50. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009, 202:419-443.
51. Richter W., Menniti F.S., Zhang H.T., Conti M. PDE4 as a target for cognition enhancement. Expert Opin Ther Targets 2013, 17:1011-1027.
52. Robichaud A., Savoie C., Stamatiou P.B., Tattersall F.D., Chan C.C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001, 40:262-269.
53. Robichaud A., Stamatiou P.B., Jin S.L., Lachance N., MacDonald D., Laliberté F., Liu S., Huang Z., Conti M., Chan C.C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002, 110:1045-1052.
54. Rojas P.S., Fritsch R., Rojas R.A., Jara P., Fiedler J.L. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res 2011, 189:239-245.
55. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994, 171:183-186.
56. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
57. Sarkisyan G., Roberts A.J., Hedlund P.B. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 2010, 209:99-108.
58. Shalaby A.M., Kamal S.M. Effect of rolipram, a phosphodiesterase enzyme type-4 inhibitor, on γ-amino butyric acid content of the frontal cortex in mice exposed to chronic mild stress. J Pharmacol Pharmacother 2012, 3:132-137.
59. Siopi E., Cho A.H., Homsi S., Croci N., Plotkine M., Marchand-Leroux C., Jafarian-Tehrani M. Minocycline restores sAPPα levels and reduces the late histopathological consequences of traumatic brain injury in mice. J Neurotrauma 2011, 28:2135-2143.
60. Siopi E., Llufriu-Dabén G., Cho A.H., Vidal-Lletjós S., Plotkine M., Marchand-Leroux C., Jafarian-Tehrani M. Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology 2013, 67:183-192.
61. Sümegi A. Domino principle-monoamines in bottom-view. Neuropsychopharmacol Hung 2008, 10:131-140.
62. Takano K., Yamasaki H., Kawabe K., Moriyama M., Nakamura Y. Imipramine induces brain-derived neurotrophic factor mRNA expression in cultured astrocytes. J Pharmacol Sci 2012, 120:176-186.
63. Tonelli L.H., Holmes A., Postolache T.T. Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 2008, 33:1038-1048.
64. Vellas B., Sol O., Snyder P.J., Ousset P.J., Haddad R., Maurin M., Lemarié J.C., Désiré L., Pando M.P. EHT0202/002 study group. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011, 8:203-212.
65. Wang P., Myers J.G., Wu P., Cheewatrakoolpong B., Egan R.W., Billah M.M. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun 1997, 1234:320-324.
66. Wang C., Yang X.M., Zhuo Y.Y., Zhou H., Lin H.B., Cheng Y.F., Xu J.P., Zhang H.T. The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int J Neuropsychopharmacol 2012, 15:749-766.
67. Wang Z.Z., Zhang Y., Liu Y.Q., Zhao N., Zhang Y.Z., Yuan L., An L., Li J., Wang X.Y., Qin J.J., Wilson S.P., O'Donnell J.M., Zhang H.T., Li Y.F. RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects. Br J Pharmacol 2013, 168:1001-1014.
68. Wolfe F., Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum 2009, 61:667-673.
69. Zeugmann S., Buehrsch N., Bajbouj M., Heuser I., Anghelescu I., Quante A. Childhood maltreatment and adult proinflammatory status in patients with major depression. Psychiatr Danub 2013, 25:227-235.
70. Zhang H.T. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009, 15:1688-1698.
71. Zhang H.T., Huang Y., Jin S.L., Frith S.A., Suvarna N., Conti M., O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002, 27:587-595.
72. Zhang K.Y., Ibrahim P.N., Gillette S., Bollag G. Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 2005, 9:1283-1305.
73. Zhang H.T., Zhao Y., Huang Y., Deng C., Hopper A.T., De Vivo M., Rose G.M., O'Donnell J.M. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology (Berl) 2006, 186:209-217.
74. Zhang J., Guo J., Zhao X., Chen Z., Wang G., Liu A., Wang Q., Zhou W., Xu Y., Wang C. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 2013, 250:230-237.